|
Fox ML, Barba P, Heras I, López-Parra M, González-Vicent M, de la Cámara R, Batlle M, Parody R, Vallejo C, Ruiz-Camps I, Vázquez L; Infectious and Non-Infectious Complications Subcommittee of the Spanish Haematopoietic Transplant Group (Grupo Español de Trasplante Hematopoyético; GETH).. A registry-based study of non-Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation. Clin Microbiol Infect. 2015 Jan;21(1):e1-3. doi: 10.1016/j.cmi.2014.08.006. PubMed PMID: 25636943.
AÑO: 2015; IF: 4.575
|
25636943
|
Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM.. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget. 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148. PubMed PMID: 26436590; PubMed Central PMCID: PMC4741628.
AÑO: 2015; IF: 5.008
|
|
Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015 Oct 2;5:e352. doi: 10.1038/bcj.2015.76. PubMed PMID: 26430723; PubMed Central PMCID: PMC4635188.
AÑO: 2015; IF: 4.411
|
|
Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J; Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias).. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia. 2014 Apr;28(4):804-12. doi: 10.1038/leu.2013.281. PubMed PMID: 24072101.
AÑO: 2014; IF: 10.431
|
|
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. PubMed PMID: 23772672.
AÑO: 2013; IF: 4.959
|